Kiniksa Pharmaceuticals (NASDAQ:KNSA) Issues Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) issued its quarterly earnings results on Tuesday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.11), Briefing.com reports. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. The firm had revenue of $79.90 million for the quarter, compared to the consensus estimate of $76.97 million. During the same period last year, the firm earned ($0.18) EPS. The company’s revenue for the quarter was up 65.4% on a year-over-year basis.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock traded up $0.64 during midday trading on Wednesday, hitting $18.32. 34,133 shares of the company’s stock were exchanged, compared to its average volume of 398,011. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of 100.84 and a beta of 0.27. The firm’s 50 day simple moving average is $19.36 and its 200 day simple moving average is $18.00. Kiniksa Pharmaceuticals has a 12-month low of $10.65 and a 12-month high of $22.09.

Insider Buying and Selling

In related news, CEO Sanj K. Patel sold 12,742 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the transaction, the chief executive officer now owns 70,594 shares of the company’s stock, valued at $1,517,065.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Sanj K. Patel sold 12,742 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the completion of the transaction, the chief executive officer now directly owns 70,594 shares in the company, valued at $1,517,065.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Michael R. Megna sold 5,126 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares in the company, valued at $383,242.52. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,109 shares of company stock valued at $709,929. Corporate insiders own 54.23% of the company’s stock.

Analyst Upgrades and Downgrades

KNSA has been the topic of a number of analyst reports. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday. TheStreet raised shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a report on Thursday, February 29th.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.